Neurim Pharmaceuticals (1991) Ltd v Generic Partners Pty Ltd

Link copied
Case Copied 25 min read

FEDERAL COURT OF AUSTRALIA

Neurim Pharmaceuticals (1991) Ltd v Generic Partners Pty Ltd [2018] FCA 1082

File number: NSD 656 of 2017
Judge: NICHOLAS J
Date of judgment: 24 July 2018
Catchwords:

PATENTS – legal professional privilege/patent attorney privilege – whether implied waiver – application by patentee to amend patent pursuant to s 105 of Patents Act 1990 (Cth) – delay – where patentee alleges that it did not decide that it would be desirable to amend patent until shortly prior to filing of application under s 105 – whether implied waiver arising from patentee’s pleaded grounds in support of proposed amendments in relation to advice given to patentee concerning amendments made to patent applications filed in other jurisdictions

PRIVILEGE – legal professional privilege/patent attorney privilege – whether implied waiver

Legislation:

Intellectual Property Laws Amendment (Raising the Bar) Act 2012 (Cth)

Patents Act 1990 (Cth) s 105(1)

Cases cited:

Commissioner of Taxation v Rio Tinto Ltd (2006) 151 FCR 341

Council of the New South Wales Bar Association v Archer (2008) 72 NSWLR 236

CSL Ltd v Novo Nordisk Pharmaceuticals Pty Ltd (2010) 87 IPR 134

DSE (Holdings) Pty Ltd v Intertan Inc (2003) 127 FCR 499

Ferella & Anor v Official Trustee in Bankruptcy (2010) 188 FCR 68

Macquarie Bank v Arup [2016] FCAFC 117

Mann v Carnell (1999) 201 CLR 1

Smith Kline & French Laboratories Ltd v Evans Medical Ltd [1989] 1 FSR 561

Telstra Corporation Ltd v BT A/asia Pty Ltd (1998) 85 FCR 152

Thomason v Campbelltown Municipal Council (1939) 39 SR (NSW) 347

United States Surgical Corp v Hospital Products International Pty Ltd (unreported, Supreme Court, NSW, McLelland J, 13 October 1981)

Date of hearing: 17 May 2018
Registry: New South Wales
Division: General Division
National Practice Area: Intellectual Property
Sub-area: Patents and associated Statutes
Category: Catchwords
Number of paragraphs: 57
Counsel for the Applicant: Mr D Shavin QC with Ms L Thomas
Solicitor for the Applicant: DLA Piper Australia
Solicitor for the First Respondent: Mr S Sloan of Dentons
Counsel for the Second Respondent: Mr N Murray with Ms F St John
Solicitor for the Second Respondent: Herbert Smith Freehills

ORDERS

NSD 656 of 2017
BETWEEN:

NEURIM PHARMACEUTICALS (1991) LTD

Applicant

AND:

GENERIC PARTNERS PTY LTD (ACN 132 833 777)

First Respondent

APOTEX PTY LTD (ACN 096 916 148)

Second Respondent

JUDGE:

NICHOLAS J

DATE OF ORDER:

24 July 2018

THE COURT ORDERS THAT:

1.The interlocutory application be dismissed.

2.The respondents pay the applicant’s costs of the interlocutory application.

Note:   Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.


REASONS FOR JUDGMENT

NICHOLAS J:

BACKGROUND

  1. Before me is an interlocutory application brought by the second respondent (“Apotex”) which, in substance, challenges claims for legal professional privilege and patent attorney privilege made by the applicant (“Neurim”), in respect of certain documents.  The first respondent (“Generic Partners”) supports Apotex’s application and adopts its submissions.

  2. The application arises in a proceeding for infringement of Australian Patent No 2002326114 (“the…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Neurim Pharmaceuticals (1991) Ltd v Generic Partners Pty Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2018] FCA 1082
Decision Date

CaseChat Overview and Summary

Neurim Pharmaceuticals (1991) Ltd applied to amend its Australian patent for melatonin-based sleep aids. Generic Partners Pty Ltd opposed the amendment, arguing it was delayed and that Neurim had waived legal professional privilege over documents related to the patent. The Federal Court of Australia examined whether Neurim's delay in seeking amendments and its assertions about its state of mind at the time constituted a waiver of privilege. The court considered the relevance of Neurim's prior knowledge and understanding of the desirability of amending the patent, as well as the impact of any legal advice received on Neurim's decision-making process.

The court found that for a waiver to occur, it must be shown that the documents in question were likely to have affected Neurim's state of mind or that of a reasonable person in Neurim's position in some relevant way. The court held that Neurim's assertion that it did not decide that it would be desirable to amend the patent until shortly before filing the application under section 105 of the Patents Act 1990 did not constitute a waiver of privilege. The court found that Neurim did not make any express or implied assertion as to the effect of the legal advice it received regarding the amendment of the patent. The court also found that there was no inconsistency in Neurim maintaining its claim for privilege in relation to the advice it received during the prosecution of the European and United States patent applications, while asserting that it did not receive any advice in relation to the amendment of the Australian patent until in or about April 2017.

The court dismissed the interlocutory application and ordered the respondents to pay the applicant's costs of the interlocutory application. The court held that the fact that the relevant communication was unlikely to have had more than a peripheral or incidental impact on Neurim's state of mind precluded a finding of waiver. The court also held that even if the communication had affected Neurim's state of mind, there was no inconsistency in Neurim putting its state of mind in issue and withholding the documents in issue in circumstances that gave rise to some unfairness to the respondents. The court found that Neurim's assertion that a reasonable person in its position would not have decided that it was necessary or desirable to amend the patent until in or about April 2017 did not constitute a waiver of privilege.

Orders

Orders of the court

1. The interlocutory application be dismissed.

2. The respondents pay the applicant’s costs of the interlocutory application.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

I note that it is not disputed by Apotex that there are no documents within category 1(b)(ii) which relate to Canadian Patent No 2,454,699 (“the Canadian Patent”). Nor does Apotex dispute that the documents in issue would be privileged from production were it not for what Apotex asserts is an implied waiver of the privilege. THE EVIDENCE Professor Nava Zisapel is the Managing Director, and Chief Scientific Officer, of Neurim. She has made an affidavit which Neurim intends to read at the hearing of the amendment application. That affidavit was relied upon for the purposes of the application that is before me. Professor Zisapel was not cross-examined. In her affidavit Professor Zisapel identifies the amendments that Neurim seeks to make to the patent and Neurim’s reasons for seeking them. Her affidavit also provides a brief prosecution history of the Patent, the European Patent, the United States Patent and the Canadian Patent. She also provides a description of the steps taken by Neurim leading up to the filing of the amendment application. Professor Zisapel says she first discussed the possibility of amending the Patent with Mr Tyacke in a telephone conference on 23 March 2017. She says this was the first time the possibility of amending the Patent was suggested to her or, to her knowledge, Neurim. She says that, to her knowledge, Neurim had not previously considered the prospect of amending the Patent. Various amendments were proposed during the prosecution of the European Patent on 4 December 2008, 2 February 2011 and 10 August 2011. On those dates Neurim’s patent attorneys filed a response to the First Examination Report including proposed amendments to the claims. The European Patent was not granted until 17 February 2017. Professor Zisapel says that the amendments proposed to the Patent are generally based on amendments that were made during the prosecution of the application for the European Patent. Some of the proposed amendments also reflect amendments that were made during the prosecution of the United States Patent. Professor Zisapel says in her affidavit at [71]-[72]:[71]On 23 March 2017, I held a telephone conference with other Neurim staff, Mr Tyacke and some of his team from DLA Piper. During that telephone conference, Mr Tyacke raised for the first time the idea of amending the Australian Patent. Mr Tyacke explained that he had reviewed the prosecution file for the European Patent, which had not yet been granted at this time. He advised that he considered it very likely that, if proceedings were brought for infringement of the Australian Patent, a cross-claim for invalidity would be brought relying on grounds identified in that prosecution file.[72]This was the first time that the possibility of amending the Australian Patent was suggested to me or, to my knowledge, Neurim. I and, to my knowledge, Neurim had not previously considered the prospect of amending the Australian Patent. Professor Zisapel also says in her affidavit at [94]:… the idea of amending the Australian patent was raised with Neurim by DLA Piper in late March 2017. Neurim’s rationale for seeking the amendments is that they would narrow the scope of the claims of the Australian patent, such that the scope of the issues that would potentially be litigated would be narrower. This could save time and resources for Neurim, as well as other parties and the court. Other amendments will narrow the claims in order to avoid a potential dispute in relation to the use of therapeutic agents other than melatonin, avoid a dispute in respect of the patient population of which the claims are directed and narrow the claims by limiting the nature of the medicament and the identified dosage range. She also says she is of the view that the Patent is valid but acknowledges that the court may take a different view and that, as a result, it is possible that the proposed amendments, if made, could improve Neurim’s prospects of successfully defending a challenge to the validity of the Patent.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

The fact that the relevant communication is unlikely to have had more than a peripheral or incidental impact on the party’s state of mind is likely to preclude a finding of waiver unless the party whose state of mind is in issue makes some express or implied assertion as to the content of the relevant communication. CONSIDERATION It is common ground that Neurim’s prior knowledge and understanding as to the desirability of amending the Patent is a relevant issue in the amendment application. This would be true even if Apotex had not raised the issue of delay as a ground upon which it relies in opposing the proposed amendments: see CSL Ltd v Novo Nordisk Pharmaceuticals Pty Ltd (2010) 87 IPR 134 at [20] per Jessup J citing Smith Kline & French Laboratories Ltd v Evans Medical Ltd [1989] 1 FSR 561 at 569. Neurim’s pleaded grounds in support of its amendment application allege that Neurim seeks to amend the claims to (inter alia) better align the claims with the claims of the European Patent. It also alleges that Neurim did not decide that it would be desirable to amend the Patent until about April 2017 and that a reasonable person in Neurim’s position would also have not decided that it would be desirable to amend the Patent before then. It is important to distinguish at least two possible scenarios, one in which Neurim asserted that it had received legal advice that it was neither necessary nor desirable to seek to amend the Patent, and the other, in which it asserted that it received no advice at all on the topic before March or April 2017. The present case is within the second category. Neurim is not seeking to rely on the legal advice it obtained during the prosecution of either the European Patent Application or the United States Patent Application nor is it making any express or implied assertion as to the effect of that advice. I do not see any inconsistency in Neurim maintaining its claim for privilege in relation to such advice as it did receive in the course of prosecuting those applications while bringing a case in which it asserts that it did not receive any advice in relation to the amendment of the Patent until in or about April 2017. However, as previously explained, it may be sufficient to bring about a waiver if the person claiming privilege makes assertions about his or her state of mind in circumstances where the confidential communications are likely to have affected that state of mind (Archer at [48]). The allegation that a reasonable person in Neurim’s position would not have decided that it was necessary or desirable to amend the Patent until in or about April 2017 would usually be addressed by reference to the information that was available to Neurim which may, of course, include any legal advice Neurim received relevant to that decision. But the fact that the legal advice is relevant to the decision to amend does not of itself bring about a waiver of privilege. It must first be shown that the documents in issue are likely to have affected Neurim’s state of mind, or that of a reasonable person in Neurim’s position, in some relevant way. Even then, a waiver will only arise where there is an inconsistency in Neurim putting its state of mind in issue and withholding the documents in issue in circumstances that give rise to some unfairness to the respondents.